BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx (LUNG)PulmonxCompany update

Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung

Related news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

XAIRBeyond Air2026-07-30 11:00 EST

Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

LUNGPulmonx2026-06-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-04-29 20:05 EST

Pulmonx Reports First Quarter 2026 Financial Results

Stock data

Close
2.26 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States